Drug Type Trispecific T-cell engager (TriTE) |
Synonyms- |
Target |
Mechanism 4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists), CD3 stimulants(T cell surface glycoprotein CD3 stimulants), DLL3 inhibitors(Delta-like protein 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Small Cell Lung Cancer | Preclinical | CN | 05 Nov 2024 |